Skip to content

Constitution of a Prospective Cohort of Patients With Acute Suppurative Hidrosadenitis Followed in the Great West: the COVER Cohort (Verneuil Cohort)

Constitution of a Prospective Cohort of Patients With Acute Suppurative Hidrosadenitis Followed in the Great West: the COVER Cohort (Verneuil Cohort)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04352036
Acronym
COVER
Enrollment
465
Registered
2020-04-17
Start date
2022-01-04
Completion date
2030-02-20
Last updated
2025-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Hidrosadenitis

Brief summary

Our primary objective with this cohort will be to define the different phenotypes of acute hidrosadenitis, the characterization of which is essential to define suitable therapeutic approaches. Indeed, our recent data allow us to note that there would be different phenotypes of acute hidrosadenitis and therefore different pathologies inducing different follow-ups and care.

Interventions

no interventional study

Sponsors

Nantes University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patient diagnosed with acute hidrosadenitis by a dermatologist * Patient agreeing to be part of the study

Exclusion criteria

* Major under guardianship * Protected persons

Design outcomes

Primary

MeasureTime frameDescription
Identify the environmental factors associated with the chronicity of the diseasethrough study completion, an average of 3 yearssocio-demographic data
Definition of different phenotypes of acute hidrosadenitisthrough study completion, an average of 3 yearspatient history, Canoui-Poitrine and van der Zee and Jemec classification, blood and urine tests, imaging
Description of the natural history and identification of the different clinical forms of acute hidrosadenitisthrough study completion, an average of 3 yearshistory of the disease, classification of Hurley, Canoui-Poitrine and van der Zee and Jemec
Prevalence of severe forms (grade II, III)through study completion, an average of 3 yearsNumber of patients with severe disease (grades II and III)

Countries

France

Contacts

Primary ContactBrigitte Dreno, PU-PH
brigitte.dreno@wanadoo.fr0240083118

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026